<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.116385</article-id><article-id pub-id-type="publisher-id">ACM-43118</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210600000_82036095.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  T-DM1在实体瘤研究中的进展及安全性评估
  The Progress and Safety Assessment of T-DM1 in Solid Tumor Research
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>根利</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>雪</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>玲</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>袁</surname><given-names>胜利</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>大连医科大学教学医院青岛市市立医院，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛大学附属青岛市市立医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>06</month><year>2021</year></pub-date><volume>11</volume><issue>06</issue><fpage>2663</fpage><lpage>2669</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  人表皮生长因子受体2 (HER2)基因的扩增在乳房、胃肠道、呼吸道、生殖道、泌尿道、皮肤和胎盘的上皮细胞的细胞膜上都可以检测到，在心脏和骨骼肌细胞上也可以检测到，HER-2过表达与侵略性表型和预后不良有关。因此，HER-2已成为许多抗癌治疗方法的重点。T-DM1是由曲妥珠单抗、细胞毒性药物DM1通过连接子偶联而成的抗体药物偶联物，具有靶向性和细胞毒杀伤双重抗肿瘤作用。在这篇综述中我们旨在总结有关T-DM1在各实体瘤研究中的进展及安全性和毒性的最新文献，有助于指导T-DM1的临床应用。
   The human epidermal growth factor receptor 2 (HER-2) expression can be detected on cell membranes of epithelial cells in the gastro-intestinal tract, respiratory tract, reproductive tract, urinary tract, skin, breast and placenta, but also on heart and skeletal muscle cells. HER-2 overexpression is associated with an aggressive phenotype and poor prognosis. HER-2, therefore, has become the focus of many cancer treatments. T-DM1 is an antibody drug conjugate formed by the trastuzumab and cytotoxic drug DM1, which has both targeting and cytotoxicity. In this review, we aim to summarize the latest literature on the research progress, safety and toxicity of T-DM1 in various solid tumors to help guide the clinical application of T-DM1.
 
</p></abstract><kwd-group><kwd>HER-2，T-DM1，实体瘤，安全性, HER-2</kwd><kwd> T-DM1</kwd><kwd> Solid Tumor</kwd><kwd> Safety</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>人表皮生长因子受体2 (HER2)基因的扩增在乳房、胃肠道、呼吸道、生殖道、泌尿道、皮肤和胎盘的上皮细胞的细胞膜上都可以检测到，在心脏和骨骼肌细胞上也可以检测到，HER-2过表达与侵略性表型和预后不良有关。因此，HER-2已成为许多抗癌治疗方法的重点。T-DM1是由曲妥珠单抗、细胞毒性药物DM1通过连接子偶联而成的抗体药物偶联物，具有靶向性和细胞毒杀伤双重抗肿瘤作用。在这篇综述中我们旨在总结有关T-DM1在各实体瘤研究中的进展及安全性和毒性的最新文献，有助于指导T-DM1的临床应用。</p></sec><sec id="s2"><title>关键词</title><p>HER-2，T-DM1，实体瘤，安全性</p></sec><sec id="s3"><title>The Progress and Safety Assessment of T-DM1 in Solid Tumor Research<sup> </sup></title><p>Genli Liu<sup>1*</sup>, Xue Yang<sup>2</sup>, Ling Li<sup>2</sup>, Shengli Yuan<sup>2#</sup></p><p><sup>1</sup>Dalian Medical University Teaching Hospital Qingdao Municipal Hospital, Qingdao Shandong</p><p><sup>2</sup>Qingdao Municipal Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/27-1572312x4_hanspub.png" /></p><p>Received: May 10<sup>th</sup>, 2021; accepted: May 29<sup>th</sup>, 2021; published: Jun. 15<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/27-1572312x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>The human epidermal growth factor receptor 2 (HER-2) expression can be detected on cell membranes of epithelial cells in the gastro-intestinal tract, respiratory tract, reproductive tract, urinary tract, skin, breast and placenta, but also on heart and skeletal muscle cells. HER-2 overexpression is associated with an aggressive phenotype and poor prognosis. HER-2, therefore, has become the focus of many cancer treatments. T-DM1 is an antibody drug conjugate formed by the trastuzumab and cytotoxic drug DM1, which has both targeting and cytotoxicity. In this review, we aim to summarize the latest literature on the research progress, safety and toxicity of T-DM1 in various solid tumors to help guide the clinical application of T-DM1.</p><p>Keywords:HER-2, T-DM1, Solid Tumor, Safety</p><disp-formula id="hanspub.43118-formula13"><graphic xlink:href="//html.hanspub.org/file/27-1572312x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/27-1572312x8_hanspub.png" /> <img src="//html.hanspub.org/file/27-1572312x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>HER-2被认为与患者不良预后相关，随着靶向药物的问世，患者的预后得到了明显的提高。T-DM1是一种新型的抗体–药物共轭复合物，是由一种细胞毒性药物(美坦新的衍生物)与曲妥珠单抗共轭结合而成。此种ADC (antibody-drug conjugate, ADC)目标是将细胞毒性药物传递给肿瘤细胞，同时发挥曲妥珠单抗的靶向作用和DM1的细胞毒性作用，减少了细胞毒性药物与正常组织细胞作用所致的不良反应。T-DM1作用不完全依赖于HER-2下游信号通路，可以克服由于信号通路异常所致的曲妥珠单抗耐药 [<xref ref-type="bibr" rid="hanspub.43118-ref1">1</xref>]。并且对曲妥珠单抗和拉帕替尼均耐药的细胞仍有抗肿瘤活性 [<xref ref-type="bibr" rid="hanspub.43118-ref2">2</xref>]。T-DM1是首个应用于实体瘤的ADC药物。由于T-DM1具有良好的安全性，因此报告毒性过大的研究相对较少。但是，考虑到T-DM1的使用越来越多，需要对其毒性进行全面评估。在这篇综述中，我们总结了有关T-DM1在各实体瘤中的研究进展及重要不良事件(adverse effect, AE)的当前可用文献，作为临床实践的纲要。</p></sec><sec id="s6"><title>2. 乳腺癌</title><p>根据2020年最新全球癌症数据提示，乳腺癌已取代肺癌成为全球第一大癌。众所周知，乳腺癌是一种生物异质性疾病，具有多种亚型，不同亚型的治疗方式及预后差别较大。约有15%~20%的乳腺癌患者伴有HER-2基因的过度表达，生物学行为表现为易复发、总生存期短。曲妥珠单抗、帕妥珠单抗的引入极大的改善了HER-2阳性乳腺癌患者的预后，2013年，美国食品药品监督管理局(FDA)和欧洲药品管理局(EMA)批准了T-DM1用于治疗HER-2阳性晚期乳腺癌。在HER-2阳性晚期乳腺癌一线、二线以及多线治疗的临床研究中，T-DM1均显示出突出的抗肿瘤活性，且耐受性良好。由此引发了T-DM1在新辅助及辅助阶段的相关研究。</p><sec id="s6_1"><title>2.1. 晚期乳腺癌治疗</title><p>EMILIA试验是一项大型的III期试验，将先前曾接受曲妥珠单抗和紫杉烷治疗的HER2阳性晚期991名乳腺癌患者随机分配至T-DM1或拉帕替尼加卡培他滨。主要终点是无进展生存期、总体生存期和安全性。在两次总体生存期中期分析中，T-DM1治疗较拉帕替尼加卡培他滨组显著改善了无进展生存期(中位生存期为9.6个月，而拉帕替尼加卡培他滨组为6.4个月)和中位总体生存期(30.9个月，而拉帕替尼联合卡培他滨组为25.1个月)。同时可观察到，在基线时有CNS转移的患者中，总体生存率显著提高 [<xref ref-type="bibr" rid="hanspub.43118-ref3">3</xref>]。在T-DM1的安全性和毒性方面，拉帕替尼–卡培他滨组的3或4级不良事件发生率高于T-DM1组(57.0%对40.8%)。T-DM1最常报告的 3级或4级事件是血小板减少症(12.9%)、血清高浓度的天冬氨酸转氨酶(4.3%)和丙氨酸转氨酶升高(2.9%)，唯一报告1例4级胃肠道出血事件。T-DM1组最常见的AE是：恶心，疲劳，血小板减少，头痛，便秘，腹泻，肝酶升高，厌食和鼻出血 [<xref ref-type="bibr" rid="hanspub.43118-ref4">4</xref>]。基于此试验，T-DM1目前被批准用于治疗先前曾接受紫衫烷类加曲妥珠单抗治疗的HER2阳性转移性BC (MBC)患者。</p><p>提供相关毒性数据的其他III期研究是MARIANNE试验。此试验将1095例经过集中评估的HER2阳性晚期乳腺癌且之前没有进行过晚期疾病治疗的患者随机分配为1:1:1对照(曲妥珠单抗加紫杉烷，T-DM1加安慰剂，T-DM1加帕托珠单抗)，主要终点为无进展生存期(PFS)。与曲妥珠单抗和紫杉烷相比，T-DM1和T-DM1加帕妥珠单抗显示为非劣等PFS (中位PFS：曲妥珠单抗加紫杉烷为13.7个月，T-DM1为14.1个月，T-DM1加帕妥珠单抗为15.2个月)。两个实验组均未显示出PFS优于曲妥珠单抗和紫杉烷。与T-DM1组(45.4%)和T-DM1加帕妥珠单抗组(46.2%)相比，对照组的3级不良事件发生率在数字上更高(54.1%)。在T-DM1组中，最常报告的3级AEs为血小板减少症(7.9%)、天冬氨酸转氨酶升高(6.6%)和贫血(4.7%)，除了3级腹泻增加，在T-DM1中添加帕妥珠单抗并没有实质性增加高级别毒性的发生率 [<xref ref-type="bibr" rid="hanspub.43118-ref5">5</xref>]。因此，2016年NCCN指南将T-DM1作为HER-2阳性晚期乳腺癌的一线可选方案。目前HER-2阳性晚期乳腺癌的标准一线治疗方案是紫衫类、曲妥珠单抗联合帕妥珠单抗，NCCN指南建议T-DM1在一线治疗的应用仅限于不适合接受标准一线方案的患者。</p><p>KAMILLA试验是迄今为止接受T-DM1治疗的最大患者队列，与其他研究不同，KAMILLA的设计以安全性和耐受性为主要目标。KAMILLA评估了先前治疗过的HER2阳性局部晚期或转移性BC (晚期BC)患者中T-DM1的安全性。总体而言，有1862名(93.0%)患者报告了任何AE。427 (21.3%)位患者发生了严重的AE。与T-DM1相关的5级AE包括多器官功能障碍和脑水肿(各2例)以及败血症，肺炎，肺栓塞，间质性肺病，呼吸衰竭，药物性肝损伤，肾衰竭和急性肾损伤(1个)。一名患者发生了先前存在的脑放射坏死(与研究治疗无关)的恶化(5级事件)。最常见的3级和4级AEs为：血小板减少、肝事件(6级5位)、出血(两个5级)、CNS出血、心脏功能障碍、肺炎(大多数出血事件与3级血小板计数减少无关，5级血小板计数没有减少)。KAMILLA的中期分析发现，基线CNS转移患者中T-DM1的总体安全性与未基线CNS转移患者中观察到的总体安全性相当，T-DM1对基线CNS可测量的患者显示出有意义的抗肿瘤转移活性 [<xref ref-type="bibr" rid="hanspub.43118-ref6">6</xref>]。</p></sec><sec id="s6_2"><title>2.2. 新辅助治疗</title><p>基于T-DM1在晚期乳腺癌中突出的疗效和良好的耐受性，部分研究者将T-DM1应用于早期乳腺癌的新辅助临床研究。新辅助研究旨在探索T-DM1与化疗、靶向或者内分泌药物联合应用能否进一步提高病理学完全缓解(pathologic complete response, pCR)率。</p><p>KRISTINE研究是一项比较T-DM1联合帕妥珠单抗与TCH方案联合帕妥珠单抗方案在新辅助治疗中的有效性及安全性的试验，发现T-DM1+P组的pCR率显著低于TCH+P组，但是T-DM1+P方案安全性更好，≥3级不良事件、严重不良事件和因不良事件导致治疗终止的发生率均更低。因此对于老年或耐受性差的HER-2阳性乳腺癌患者来说，T-DM1+P方案是值得选择的新辅助治疗方案 [<xref ref-type="bibr" rid="hanspub.43118-ref7">7</xref>]。</p><p>ADAPT研究将375例HER2阳性和HR阳性的早期乳腺癌患者(筛查的n = 463)随机分配到有或没有内分泌治疗的T-DM1或内分泌治疗联合曲妥珠单抗。T-DM1组中的pCR率超过40%，该结果提示，含T-DM1的新辅助治疗方案在较短时间内即可获得较高的pCR率，支持在HER2阳性/HR阳性疾病中使用含T-DM1的新辅助疗法，而曲妥珠单抗和内分泌治疗的pCR率较低，因此在临床上不鼓励这种组合可行的选择。安全性方面，多数AEs的转氨酶升高，据报告有17种与治疗相关的严重AE，一种ALT升高，一种角膜囊肿，一种高血压危象和一种超敏反应；所有患者均康复，无后遗症。总之，未检测到T-DM1的新安全性信号，所有三个治疗组的总体毒性均良好 [<xref ref-type="bibr" rid="hanspub.43118-ref8">8</xref>]。</p></sec><sec id="s6_3"><title>2.3. 辅助治疗</title><p>KATHERINE是一项3期开放试验，涉及HER2阳性早期乳腺癌患者，这些患者在接受含有紫杉烷(含或不含蒽环类)和曲妥珠单抗的新辅助治疗后，在手术中发现乳房或腋窝残留侵袭性疾病。患者被随机分配至T-DM1或曲妥珠单抗组。接受T-DM1的患者的无侵袭性无病生存(主要终点)显著高于接受曲妥珠单抗的患者。安全性方面，3级或更高级别的最常见不良事件是T-DM1组的血小板计数降低和高血压。在T-DM1组中，导致T-DM1组停用试验药物的最常见不良事件是血小板减少(4.2%)、血液胆红素水平升高(2.6%)、天冬氨酸氨基转移酶升高(1.6%)、丙氨酸氨基转移酶水平增加(1.5%)、外周感觉神经病变(1.5%)和射血分数减少(1.2%)。T-DM1组发生了2例肝结节性再生增生的判定病例。T-DM1组中的1名患者死于与跌倒和2级血小板减少症相关的颅内出血 [<xref ref-type="bibr" rid="hanspub.43118-ref9">9</xref>]。</p></sec></sec><sec id="s7"><title>3. 胃癌</title><p>HER2在许多组织中，包括乳腺，胃肠道，肾脏和心脏中表达 [<xref ref-type="bibr" rid="hanspub.43118-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.43118-ref11">11</xref>]。HER2状态与胃癌患者预后之间的关系仍存在争议。胃癌HER2检测指南建议转移性或复发性胃癌患者应常规进行HER2检测。曲妥珠单抗联合化疗已获批准用于晚期一线胃癌或胃食管交界性HER2阳性转移性腺癌的患者。此批准基于曲妥珠单抗用于胃癌(ToGA)研究的关键数据，该数据表明将曲妥珠单抗加入化疗(卡培他滨或氟尿嘧啶与顺铂)可显著改善HER2阳性晚期胃癌(AGC)患者的总体生存率(OS) [<xref ref-type="bibr" rid="hanspub.43118-ref12">12</xref>]。且曲妥珠单抗加化疗(包括卡培他滨)是治疗HER-2阳性晚期胃癌的一线治疗标准疗法 [<xref ref-type="bibr" rid="hanspub.43118-ref13">13</xref>]。这些研究表明，曲妥珠单抗联合化疗药物可明显增加疗效。设想T-DM1联合卡培他滨在治疗转移性胃癌可能显示出功效。</p><p>GATSBY试验是一项关于T-DM1与紫杉烷类药物用于二线HER2阳性局部晚期或转移性胃或胃食管交界处腺癌的研究。T-DM1组与紫杉醇组相比，尽管T-DM1具有抗肿瘤活性，但并未能达到其总体生存优势的主要终点，并未延长无进展生存期。安全性方面，与其在转移性乳腺癌患者中的使用一致，未发现新的安全信号。T-DM1组发生3级或更高级别不良事件的发生率比使用紫杉烷类药物治疗的不良事件更低。接受T-DM1的患者中常见的3级或以上不良事件为贫血和血小板减少症。常见的严重不良事件为贫血和上消化道出血。有8名(4%)发生了导致死亡的不良事件(这些事件是胃出血，上消化道出血，非典型肺炎，败血性休克，肺炎吸入和肺部出血各1例，肺炎2例)。患者对T-DM1的耐受性良好 [<xref ref-type="bibr" rid="hanspub.43118-ref14">14</xref>]。</p><p>其中一项关于探索生物标记物的亚组分析提示先前治疗过HER2表达较高的HER2阳性AGC的患者，其T-DM1的治疗效果优于那些较低HER2表达的患者，并可能从T-DM1和紫杉烷治疗中获得相当的生存获益，高和低HER2表达之间的差异性治疗优势对PFS而言比对OS更为明显 [<xref ref-type="bibr" rid="hanspub.43118-ref15">15</xref>]。且ToGA试验中总体肿瘤应答率为47.1%，其中77.6%的患者HER2 IHC 3+或IHC 2+/ISH阳性，这表明尽管HER2过表达，但仍有相当一部分患者对曲妥珠单抗一线治疗无反应，这表明HER2在胃癌中的过度表达通常是异质的。</p></sec><sec id="s8"><title>4. 非小细胞肺癌(Non-Small Cell Lung Cancer, NSCLC)</title><p>肺癌目前仍是全球死亡率第一的癌症，其中NSCLC占肺癌总数的80%~85%，HER-2是一种酪氨酸激酶受体，与EGFR协同激活下游信号传导。虽然HER-2在NSCLC中突变频率较EGFR低，但是其肺癌驱动机制明确且部分靶向治疗有效，最近基于驱动癌基因的精确疗法已大大改变了NSCLC的治疗策略，然而，HER-2突变的肿瘤对化疗敏感性较差，即使采用标准化学疗法，其他肺癌的疗效仍然较差 [<xref ref-type="bibr" rid="hanspub.43118-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.43118-ref17">17</xref>]。因此，有必要进一步开发新型致癌基因和相应的靶向治疗剂。T-DM1在HER-2阳性晚期乳腺癌中的治疗优势，且在肺癌的临床前研究表明，T-DM1可能对HER2阳性的肺癌有效 [<xref ref-type="bibr" rid="hanspub.43118-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.43118-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.43118-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.43118-ref21">21</xref>]。基于以上相关研究，报告了T-DM1单药治疗复发的NSCLC的一项II期临床试验，T-DM1在这项研究中未显示出很高的疗效，特别是，在这项研究中，IHC 3+或IHC 2+/FISH阳性肿瘤很少对研究药物有反应。由于疗效有限，该实验提早终止。几乎所有AE都是已知的，主要是血小板减少症和肝毒性，一例3级急性肾衰竭，一例2级间质性肺炎，在15例患者中，没有因治疗而死亡的病例 [<xref ref-type="bibr" rid="hanspub.43118-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.43118-ref23">23</xref>]。这与T-DM1在胃癌GATSBY试验中结论相似 [<xref ref-type="bibr" rid="hanspub.43118-ref14">14</xref>]。</p><p>另一项II期试验来自美国的Bob T Li团队 [<xref ref-type="bibr" rid="hanspub.43118-ref24">24</xref>]，18例晚期HER2突变型肺腺癌患者，先前全身治疗的中位数为2，达到主要终点的部分反应率为44%。在HER2外显子20插入且激酶跨膜和细胞外结构域中存在点突变的患者中观察到了反应，在两名患者中观察到同时的HER2扩增，HER2免疫组化范围是0到2+，不能预测应答，并且通过质谱法测定，应答者的HER2蛋白表达较低。中位无进展生存期为5个月。毒性包括1或2级输注反应，血小板减少症和肝转氨酶升高。没有患者因毒性而停止治疗或死于研究。得到T-DM1是HER2突变型肺癌患者的活性药物的结论。这是肺癌HER2分子亚群的第一个阳性临床研究。</p></sec><sec id="s9"><title>5. 小结与展望</title><p>综上所述，T-DM1在各种实体瘤中耐受性高，在应用过程中，要注意监测血液学相关指标，注意有无合并出血风险，予以减量或停药及相关对症处理。T-DM1在乳腺癌各阶段均表现出良好的疗效，但是在晚期二线胃癌、晚期非小细胞肺癌中疗效有限，从而引发了我们的一系列思考，原因可能与肿瘤异质性相关 [<xref ref-type="bibr" rid="hanspub.43118-ref25">25</xref>]，也可能与T-DM1的原发性和继发性耐药相关 [<xref ref-type="bibr" rid="hanspub.43118-ref26">26</xref>]，一线治疗后，有证据表明，由于肿瘤分子谱的变化，HER-2的状态在进展过程中可能会改变或丢失，据报道，HER-2在原发性和转移性肿瘤之间表达不一致 [<xref ref-type="bibr" rid="hanspub.43118-ref27">27</xref>] [<xref ref-type="bibr" rid="hanspub.43118-ref28">28</xref>]。尚不清楚HER-2的局部表达如何影响T-DM1的活性，需要进一步的研究来了解HER-2过表达在生物学中的作用。目前，关于T-DM1在各实体瘤中，包括延腺癌、膀胱癌、胰腺癌、胆管细胞癌、结直肠癌等相关临床前研究及临床试验正在进行中，未来临床试验的结果将阐明一线HER2靶向治疗失败后，以联合疗法而非单一疗法靶向HER2途径还是通过激活免疫细胞将提高疗效。我们期待得到更好的数据，进一步延长肿瘤患者生存期。</p></sec><sec id="s10"><title>文章引用</title><p>刘根利,杨 雪,李 玲,袁胜利. T-DM1在实体瘤研究中的进展及安全性评估The Progress and Safety Assessment of T-DM1 in Solid Tumor Research[J]. 临床医学进展, 2021, 11(06): 2663-2669. https://doi.org/10.12677/ACM.2021.116385</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43118-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Krop, I.E., Kim, S.B., Gonzlez-Martin, A., et al. (2014) Trastuzumab Emtanaine versus Treatment of Physician HER2-Positive Advanced Breast Cancer (TH3RESA): A Randomised, Open-Lable, Phase 3 Trial. The Lancet Oncology, 15, 689-699. &lt;br&gt;https://doi.org/10.1016/S1470-2045(14)70178-0</mixed-citation></ref><ref id="hanspub.43118-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Lewis-Phillips, G., Li, G.D., Crocker, L., et al. (2008) Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate. Cancer Research, 68, 9280-9290. &lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-08-1776</mixed-citation></ref><ref id="hanspub.43118-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Krop, I.E., Lin, N.U., Blackwell, K., et al. (2015) Trastuzumab Emtansine (T-DM1) versus Lapatinib plus Capecitabine in Patients with HER2-Positive Metastatic Breast Cancer and Central Nervous System Metastases: A Retrospective, Exploratory Analysis in Emilia. Annals of Oncology, 26, 113-119. &lt;br&gt;https://doi.org/10.1093/annonc/mdu486</mixed-citation></ref><ref id="hanspub.43118-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Verma, S., Miles, D., Gianni, L., et al. (2012) Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. The New England Journal of Medicine, 367, 1783-1791. &lt;br&gt;https://doi.org/10.1056/NEJMoa1209124</mixed-citation></ref><ref id="hanspub.43118-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Perez, E.A., Barrios, C., Eiermann, W., et al. (2017) Trastuzumab Emtansine with or without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results from the Phase III MARIANNE Study. Journal of Clinical Oncology, 35, 141-148.  
&lt;br&gt;https://doi.org/10.1200/JCO.2016.67.4887</mixed-citation></ref><ref id="hanspub.43118-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Montemurro, F., Ellis, P., Anton, A., et al. (2019) Safety of Trastuzumab Emtansine (T-DM1) in Patients with HER2-Positive Advanced Breast Cancer: Primary Results from the KAMILLA Study Cohort 1. European Journal of Cancer, 109, 92-102. &lt;br&gt;https://doi.org/10.1016/j.ejca.2018.12.022</mixed-citation></ref><ref id="hanspub.43118-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Hurvitz, S.A., Martin, M., Symmans, W.F., et al. (2016) Pathologic Complete Response (pCR) Rates after Neoadjuvant Tras-Tuzumab Emtansine (T-DM1) + Pertuzumab (P) vs Docetaxel + Carboplatin + Trastuzumab + P (TCHP) Treatment in Patients with HER2-Positive (HER2+) Early Breast Cancer (EBC) (KRISTINE). Journal of Clinical Oncology, 34, 500. &lt;br&gt;https://doi.org/10.1200/JCO.2016.34.15_suppl.500</mixed-citation></ref><ref id="hanspub.43118-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Harbeck, N., Gluz, O., Christgen, M., et al. (2016) Final Analysis of WSG-ADAPT HER2+/HR+ Phase II Trial: Efficacy, Safety, and Predictive Markers for 12-Weeks of Neoad-Juvant T-DM1 with or without Endocrine Therapy versus Trastuzumab + Endocrine Therapy in HER2-Positive Hormone Receptorpositive Early Breast Cancer. Cancer Research, 76, Abstract nr S5-03. &lt;br&gt;https://doi.org/10.1158/1538-7445.SABCS15-S5-03</mixed-citation></ref><ref id="hanspub.43118-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">von Minckwitz, G., Huang, C.S., Mano, M.S., et al. (2019) Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. The New England Journal of Medicine, 380, 617-628.</mixed-citation></ref><ref id="hanspub.43118-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Uhlen, M., Fagerberg, L., Hallstrom, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, A., Kampf, C., Sjostedt, E., Asplund, A., et al. (2015) Proteomics. Tissue-Based Map of the Human Proteome. Science, 347, 1260419.  
&lt;br&gt;https://doi.org/10.1126/science.1260419</mixed-citation></ref><ref id="hanspub.43118-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Press, M.F., Cordon-Cardo, C. and Slamon, D.J. (1990) Expression of the HER-2/Neu Proto-Oncogene in Normal Human Adult and Fetal Tissues. Oncogene, 5, 953-962.</mixed-citation></ref><ref id="hanspub.43118-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Bang, Y.J., Van Cutsem, E., Feyereislova, A., Chung, H.C., Shen, L., Sawaki, A., et al. (2010) Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. The Lancet, 376, 687-697. &lt;br&gt;https://doi.org/10.1016/S0140-6736(10)61121-X</mixed-citation></ref><ref id="hanspub.43118-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Waddell, T., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., Arnold, D., et al. (2013) Gastric Cancer: ESMOESSO-ESTRO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 24, vi57-vi63. &lt;br&gt;https://doi.org/10.1093/annonc/mdt344</mixed-citation></ref><ref id="hanspub.43118-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Thuss-Patience, P.C., Shah, M.A., Ohtsu, A., et al. (2017) Trastuzumab Emtansine versus Taxane Use for Previously Treated HER2-Positive Locally Advanced or Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma (GATSBY): An International Randomised, Open-Label, Adaptive, Phase 2/3 Study. The Lancet Oncology, 18, 640-653.  
&lt;br&gt;https://doi.org/10.1016/S1470-2045(17)30111-0</mixed-citation></ref><ref id="hanspub.43118-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Shah, M.A., Kang, Y.K., Thuss-Patience, P.C., et al. (2019) Biomarker Analysis of the GATSBY Study of Trastuzumab Emtansine versus a Taxane in Previously Treated HER2-Positive Advanced Gastric/Gastroesophageal Junction Cancer. Gastric Cancer, 22, 803-816. &lt;br&gt;https://doi.org/10.1007/s10120-018-00923-7</mixed-citation></ref><ref id="hanspub.43118-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Hotta, K., Fujiwara, Y., Matsuo, K., et al. (2007) Recent Improvement in the Survival of Patients with Advanced Non-Small-Cell Lung Cancer Enrolled into Phase III Trials of First-Line Systemic Chemotherapy. Cancer, 109, 939-948. &lt;br&gt;https://doi.org/10.1002/cncr.22478</mixed-citation></ref><ref id="hanspub.43118-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Hotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M. and Tanimoto, M. (2004) Addition of Platinum Compounds to a New Agent in Patients with Advanced Non-Small-Cell Lung Cancer: A Literature Based Meta-Analysis of Randomised Trials. Annals of Oncology, 15, 1782-1789. &lt;br&gt;https://doi.org/10.1093/annonc/mdh476</mixed-citation></ref><ref id="hanspub.43118-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Lewis Phillips, G.D., Li, G., Dugger, D.L., et al. (2008) Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate. Cancer Research, 8, 9280-9290.  
&lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-08-1776</mixed-citation></ref><ref id="hanspub.43118-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Remillard, S., Rebhun, L.I., Howie, G.A. and Kupchan, S.M. (1975) Antimitotic Activity of the Potent Tumor Inhibitor Maytansine. Science, 189, 1002-1005. &lt;br&gt;https://doi.org/10.1126/science.1241159</mixed-citation></ref><ref id="hanspub.43118-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Perera, S.A., Li, D., Shimamura, T., et al. (2009) HER2YVMA Drives Rapid Development of Adenosquamous Lung Tumors in Mice That Are Sensitive to BIBW2992 and Rapa-Mycin Combination Therapy. Proceedings of the National Academy of Sciences of the United States of America, 106, 474-479. &lt;br&gt;https://doi.org/10.1073/pnas.0808930106</mixed-citation></ref><ref id="hanspub.43118-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Weiler, D., Diebold, J., Strobel, K., Aebi, S. and Gautschi, O. (2015) Rapid Response to Trastu-Zumab Emtansine in a Patient with HER2-Driven Lung Cancer. Journal of Thoracic Oncology, 10, e16-e17.  
&lt;br&gt;https://doi.org/10.1097/JTO.0000000000000424</mixed-citation></ref><ref id="hanspub.43118-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Ohashi, K., Hotta, K., Hirata, T., et al. (2017) Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol. Clinical Lung Cancer, 18, 92-95. &lt;br&gt;https://doi.org/10.1016/j.cllc.2016.06.014</mixed-citation></ref><ref id="hanspub.43118-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Hotta, K., Aoe, K., Kozuki, T., et al. (2018) A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 13, 273-279. &lt;br&gt;https://doi.org/10.1016/j.jtho.2017.10.032</mixed-citation></ref><ref id="hanspub.43118-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Li, B.T., Shen, R., Buonocore, D., et al. (2018) Ado-Trastuzumab Emtansine for Patients with HER2-Mutant Lung Cancers: Results from a Phase II Basket Trial. Journal of Clinical Oncology, 36, 2532-2537.  
&lt;br&gt;https://doi.org/10.1200/JCO.2018.77.9777</mixed-citation></ref><ref id="hanspub.43118-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Kobyakov, D.S., Avdalyan, A.M., Klimachev, V.V., Lazarev, A.F., Lushnikova, E.L. and Nepomnyaschikh, L.M. (2015) Non-Small Cell Lung Cancer: HER2 Oncogene Status. Arkhiv Patologii, 77, 3-9. (In Russian)  
&lt;br&gt;https://doi.org/10.17116/patol20157723-9</mixed-citation></ref><ref id="hanspub.43118-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Barok, M., Joensuu, H. and Isola, J. (2014) Trastuzumab Emtansine: Mechanisms of Action and Drug Resistance. Breast Cancer Research, 16, Article No. 209. &lt;br&gt;https://doi.org/10.1186/bcr3621</mixed-citation></ref><ref id="hanspub.43118-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Ishimine, Y., Goto, A., Watanabe, Y., et al. (2015) Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent? Case Reports in Gastrointestinal Medicine, 2015, Article ID: 132030. &lt;br&gt;https://doi.org/10.1155/2015/132030</mixed-citation></ref><ref id="hanspub.43118-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Janjigian, Y.Y., Riches, J.C., Ku, G.Y., et al. (2015) Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in HER2-Overexpressing Esophagogastric (EG) Tumors Treated with Trastuzumab. Journal of Clinical Oncology, 33, 63 (abstr). &lt;br&gt;https://doi.org/10.1200/jco.2015.33.3_suppl.63</mixed-citation></ref></ref-list></back></article>